新药疗法推动原发性中枢神经系统淋巴瘤的治疗进展

doi:10.3969/j.issn.1006-7795.2023.05.011

摘要/Abstract

摘要： 原发性中枢神经系统淋巴瘤是一种罕见的、具有高度侵袭性的结外非霍奇金淋巴瘤。目前尚无最佳治疗方案，以高剂量甲氨蝶呤为基础的化学药物治疗（以下简称化疗）是目前的一线治疗方案，尽管在疾病控制方面取得了一定疗效，但其不良反应和局限性仍不容忽视。随着对该病分子学领域更深层次的研究，以靶向治疗和免疫治疗为代表的新药疗法已经取得了显著的突破，不同药物疗法之间的组合探索开拓了相关治疗视野，推动了原发性中枢神经系统淋巴瘤的治疗进展。

关键词: 原发性中枢神经系统淋巴瘤, 诱导治疗, 巩固治疗, 复发/难治, 新药疗法

Abstract: Primary central nervous system lymphoma is a rare and highly aggressive extranodal non-Hodgkin lymphoma. Up to date, there is no optimal treatment strategy. Currently, high-dose methotrexate-based chemotherapy serves as the first-line approach. Despite achieving some efficacy in disease control, its toxic side effects and limitations cannot be overlooked. With deeper molecular research in this disease, the significant breakthroughs in novel drug therapies like targeted treatment and immunotherapy have achieved. The exploration of combinations between different drug therapies has expanded the horizons of related treatments, propelling advancements in the treatment of primary central nervous system lymphoma.

Key words: primary central nervous system lymphoma, induction therapy, consolidation therapy, relapse/refractory, novel drug therapies

中图分类号:

R739.4

尹硕, 陈峰, 郑晓红, 张维春柏, 李文斌. 新药疗法推动原发性中枢神经系统淋巴瘤的治疗进展[J]. 首都医科大学学报, 2023, 44(5): 775-781.

Yin Shuo, Chen Feng, Zheng Xiaohong, Zhang Weichunbai, Li Wenbin. Novel drug therapies promote the treatment progress of primary central nervous system lymphoma[J]. Journal of Capital Medical University, 2023, 44(5): 775-781.

参考文献

［1］Grommes C. Central nervous system lymphomas［J］. Continuum (Minneap Minn), 2020, 26(6): 1476-1494.
［2］Hoang-Xuan K, Deckert M, Ferreri A J M, et al. European association of neuro-oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)［J］. Neuro Oncol, 2023, 25(1): 37-53.
［3］Ball M K, Morris J M, Wood A J, et al. Ventricle-predominant primary CNS lymphomas: clinical, radiological and pathological evaluation of five cases and review of the literature［J］. Brain Tumor Pathol, 2020, 37(1): 22-30.
［4］Ostrom Q T, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019［J］. Neuro Oncol, 2022, 24(Suppl 5): v1-v95.
［5］Mendez J S, Ostrom Q T, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades［J］. Neuro Oncol, 2018, 20(5): 687-694.
［6］Houillier C, Soussain C, Ghesquières H, et al. Management and outcome of primary CNS lymphoma in the modern era: an LOC network study［J］. Neurology, 2020, 94(10): e1027-e1039.
［7］Ferreri A J M, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial［J］. Lancet, 2009, 374(9700): 1512-1520.
［8］Zheng X H, Yang S B, Chen F, et al. The efficacy and safety of cytarabine on newly diagnosed primary central nervous system lymphoma: a systematic review and meta-analysis［J］. Front Oncol, 2020, 10: 1213.
［9］Ferreri A J M, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial［J］. Lancet Haematol, 2016, 3(5): e217-e227.
［10］Omuro A, Chinot O, Taillandier L, et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial［J］. Lancet Haematol, 2015, 2(6): e251-e259.
［11］Ferreri A J M, Cwynarski K, Pulczynski E, et al. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial［J］. Leukemia, 2022, 36(7): 1870-1878.
［12］Bromberg J E C, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study［J］. Lancet Oncol, 2019, 20(2): 216-228.
［13］Schmitt A M, Herbrand A K, Fox C P, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis［J］. Hematol Oncol, 2019, 37(5): 548-557.
［14］Kasenda B, Loeffler J, Illerhaus G, et al. The role of whole brain radiation in primary CNS lymphoma［J］. Blood, 2016, 128(1): 32-36.
［15］Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial［J］. Lancet Oncol, 2010, 11(11): 1036-1047.
［16］Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase Ⅱ PRECIS study［J］. J Clin Oncol, 2019, 37(10): 823-833.
［17］Omuro A M P, Ben-Porat L S, Panageas K S, et al. Delayed neurotoxicity in primary central nervous system lymphoma［J］. Arch Neurol, 2005, 62(10): 1595-1600.
［18］Abrey L E, DeAngelis L M, Yahalom J. Long-term survival in primary CNS lymphoma［J］. J Clin Oncol, 1998, 16(3): 859-863.
［19］Omuro A M P, DeAngelis L M, Karrison T, et al. Randomized phase Ⅱ study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)［J］. J Clin Oncol, 2020, 38(15_suppl): 2501.
［20］Abrey L E, Moskowitz C H, Mason W P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis［J］. J Clin Oncol, 2003, 21(22): 4151-4156.
［21］Illerhaus G, Fritsch K, Egerer G, et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients with untreated primary central nervous system lymphoma-a multicentre study by the collaborative PCNSL study group freiburg［J］. Blood, 2012, 120(21): 302.
［22］Omuro A, Correa D D, DeAngelis L M, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma［J］. Blood, 2015, 125(9): 1403-1410.
［23］Ferreri A J M, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial［J］. Lancet Haematol, 2017, 4(11): e510-e523.
［24］Kang Z, Chen F, Lin Y, et al. HZ-a-018 is a highly selective and potent BTK inhibitor with CNS-penetrating profile for central nervous system lymphoma［J］. Blood, 2022, 140(Supplement 1): 12064.
［25］Wang Y L, Li W B, Chen F. P1197: Brutons tyrosine kinase inhibitor zanubrutinib in relapsed/refractory primary diffuse large B-cell lymphoma of central nervous system: a phase Ⅱ trial［J］. Hemasphere, 2023, 7(S3): e8453592.
［26］Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase Ⅱ proof-of-concept iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network［J］. Eur J Cancer, 2019, 117: 121-130.
［27］Grommes C, Tang S S, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma［J］. Blood, 2019, 133(5): 436-445.
［28］Narita Y S T, Nagane M, Mishima K, et al. Phase Ⅰ/Ⅱ study of tirabrutinib, a second-generation Brutons tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma［J］. Neuro Oncol, 2021, 23(1): 122-133.
［29］Zhang Y, Li Y N, Zhuang Z, et al. Preliminary evaluation of Zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of Zanubrutinib: a 13-case series［J］. Front Oncol, 2021, 11: 760405.
［30］Neelapu S S, Locke F L, Bartlett N L, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma［J］. N Engl J Med, 2017, 377(26): 2531-2544.
［31］Schuster S J, Bishop M R, Tam C S, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma［J］. N Engl J Med, 2019, 380(1): 45-56.
［32］Abramson J S, Palomba M L, Gordon L I, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study［J］. Lancet, 2020, 396(10254): 839-852.
［33］Siddiqi T, Wang X L, Blanchard M S, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma［J］. Blood Adv, 2021, 5(20): 4059-4063.
［34］Frigault M J, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial［J］. Blood, 2022, 139(15): 2306-2315.
［35］Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network［J］. Blood, 2022, 139(5): 792-796.
［36］Cook M R, Dorris C S, Makambi K H, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients［J］. Blood Adv, 2023, 7(1): 32-39.
［37］Rubenstein J L, Geng H M, Fraser E J, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma［J］. Blood Adv, 2018, 2(13): 1595-1607.
［38］Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective proof of concept phase Ⅱ study of the French oculo-cerebral lymphoma (LOC) network and the Lymphoma Study Association (LYSA)［J］. Ann Oncol, 2019, 30(4): 621-628.
［39］Tun H W, Johnston P B, DeAngelis L M, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma［J］. Blood, 2018, 132(21): 2240-2248.
［40］Chapuy B, Roemer M G M, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas［J］. Blood, 2016, 127(7): 869-881.
［41］Sharpe A H, Pauken K E. The diverse functions of the PD1 inhibitory pathway［J］. Nat Rev Immunol, 2018, 18(3): 153-167.
［42］Nayak L, Iwamoto F M, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma［J］. Blood, 2017, 129(23): 3071-3073.
［43］Hoang-Xuan K, Houot R, Soussain C, et al. First results of the Acsé pembrolizumab phase Ⅱ in the primary CNS lymphoma (PCNSL) cohort［J］. Blood, 2020, 136(Supplement 1): 15-16.
［44］Fingar D C, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression［J］. Oncogene, 2004, 23(18): 3151-3171.
［45］Korfel A, Schlegel U, Herrlinger U, et al. Phase Ⅱ trial of temsirolimus for relapsed/refractory primary CNS lymphoma［J］. J Clin Oncol, 2016, 34(15): 1757-1763.
［46］Grommes C, Pentsova E, Nolan C, et al. 335P-phase Ⅱ study of single agent buparlisib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)［J］. Ann Oncol, 2016, 27(Supplement 6): ⅵ106.